Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
Milestone Pharmaceuticals (Nasdaq: MIST) announced its participation in the Jefferies Global Healthcare Conference in New York City from June 4-6, 2024. The company's management will engage in a Fireside Chat on June 6 at 11:30 AM EDT. The event will be webcast live and available for replay for about 90 days on Milestone's website.
- Participation in a high-profile healthcare conference can enhance visibility and credibility.
- Management's involvement in a Fireside Chat reflects proactive investor engagement.
- Webcasting the event live and for replay allows broader investor access and transparency.
- No concrete financial or clinical data updates were provided in this announcement.
- Potential for minimal immediate impact on stock performance due to lack of substantial news.
MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies Global Healthcare Conference being held in New York City, NY from June 4-6, 2024.
Management will participate in a Fireside Chat on June 6th at 11:30 AM EDT. The webcast is available to watch both live and replay for approximately 90 days following the presentation in the News & Events section of Milestone's website www.milestonepharma.com.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Contact:
Kim Fox, Vice President, Communications, kfox@milestonepharma.com
Investor Relations
Chris Calabrese, ccalabrese@lifesciadvisors.com
Kevin Gardner, kgardner@lifesciadvisors.com
FAQ
When is Milestone Pharmaceuticals participating in the Jefferies Global Healthcare Conference?
What will Milestone Pharmaceuticals' management do at the Jefferies Global Healthcare Conference?
Where can I watch the webcast of Milestone Pharmaceuticals' presentation?
What is the stock symbol for Milestone Pharmaceuticals?
